The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Abstract
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001–January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non‐Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty‐seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non‐ efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non‐efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy‐based reviews is essential. We consider a 3‐year period a reasonable time frame for published updates and are working to establish a Web‐based mechanism to update the report in an ongoing manner. © 2005 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence-Based Medicine: How to Practice and Teach EBM
Sackett, D. L. (2000) · Cited by 5,950
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Evidence-Based Medicine: How to Practice and Teach EBM
Satya-Murti, S. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.284.18.2382 · Cited by 1,643
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Self-citationTRANSPLANTATION OF EMBRYONIC DOPAMINE NEURONS FOR SEVERE PARKINSON'S DISEASE
Reed, R., Reene, P. A. E. G., Reeze, R. O. E. B., Ei, W., Ouchel, W. I. D. U. M., Ao, R. I. K., Infield, W., Ulver, S. H. C., Rojanowski, J. O. Q. T., Idelberg, D. A. E., et al. (2001) · Cited by 1,001
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Cited by
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Self-citationSubthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Ou, Z., Pan, J., Tang, S., Duan, D., Yu, D., Nong, H., & Wang, Z. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.776847 · Cited by 729
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Self-citationRutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders
Enogieru, A. B., Haylett, W., Hiss, D. C., Bardien, S., & Ekpo, O. E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6241017 · Cited by 476
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Self-citationPriorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Self-citationDiagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Levodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
Tourette syndrome deep brain stimulation: A review and updated recommendations
Schrock, L. E., Mink, J. W., Woods, D. W., Porta, M., Servello, D., Visser‐Vandewalle, V., Silburn, P. A., Foltynie, T., Walker, H. C., Shahed‐Jimenez, J., et al. (2015) · Movement Disorders · doi:10.1002/mds.26094 · Cited by 282
Review: Deep brain stimulation in Parkinson’s disease
Groiss, S. J., Wojtecki, L., Südmeyer, M., & Schnitzler, A. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609339382 · Cited by 280
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Kvernmo, T., Härtter, S., & Burger, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.004 · Cited by 277
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Self-citationFeasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease
Silva de Lima, A. L., Hahn, T., Evers, L. J. W., de Vries, N. M., Cohen, E., Afek, M., Bataille, L., Daeschler, M., Claes, K., Boroojerdi, B., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189161 · Cited by 162
Stacy, M., & Hauser, R. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-006-0554-y · Cited by 83
Large-Scale Wearable Sensor Deployment in Parkinson’s Patients: The Parkinson@Home Study Protocol
Silva de Lima, A. L., Hahn, T., de Vries, N. M., Cohen, E., Bataille, L., Little, M. A., Baldus, H., Bloem, B. R., & Faber, M. J. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5990 · Cited by 63
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69
Self-citationPharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Poewe, W., & Mahlknecht, P. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2019.12.002 · Cited by 60
Self-citationCognitive-behavioral Strategies for Parkinson’s Disease: A Report of Three Cases
Macht, M., Pasqualini, M. S., & Taba, P. (2007) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-007-9065-8 · Cited by 14
Metadata
- Authors
- Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2005-04-07
- Volume
- 20
- Issue
- 5
- Pages
- 523-539
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2089797759
- Cited by
- 376
- References
- 47
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.